Clinical Trial Results
Research Sponsor: AstraZeneca AB
Treatments Studied: Tremelimumab and durvalumab
Trial Purpose: This trial was done to learn how tremelimumab
and durvalumab work and about their
safety in people with a type of advanced
liver cancer called hepatocellular
carcinoma
Protocol Number: D419CC00002
Thank you
Thank you to the participants who took part in the clinical trial for the trial treatments
tremelimumab and durvalumab.
All of the participants helped researchers learn more about tremelimumab and
durvalumab to help people with a type of advanced liver cancer called “hepatocellular
carcinoma”.
AstraZeneca AB sponsored this trial and believes it is important to share the results of
this trial with the participants and the public. An independent non-profit organization
called CISCRP helped prepare this summary of the trial results. We hope it helps the
participants understand and feel proud of their important role in medical research.
If you participated in this trial and have questions about the results, please speak with a
trial doctor or staff at your trial site.
1